NEWARK, Del., September 10, 2026 — The global Lung Cancer Diagnostics Market is entering a period of structural expansion as molecular testing, liquid biopsy, low-dose CT screening, and biomarker-driven treatment pathways reshape how lung cancer is detected and characterized. The market was valued at USD 13.30 billion in 2025, is projected to reach USD 14.30 billion in 2026, and is forecast to reach USD 29.47 billion by 2036, expanding at a 7.50% CAGR from 2026 to 2036.

Future Market Insights (FMI) estimates an incremental opportunity of approximately USD 15.17 billion over the forecast period. The procurement environment is shifting as laboratories and healthcare providers increasingly prioritize diagnostic platforms that combine multiple biomarker tests, support faster treatment decisions, and accommodate the growing volume of patients entering screening and targeted-therapy pathways.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-26251

Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends

Key Market Highlights at a Glance

2025 Market Value: USD 13.30 billion
2026 Market Value: USD 14.30 billion
2036 Market Forecast: USD 29.47 billion
CAGR, 2026–2036: 7.50%
Incremental Opportunity: USD 15.17 billion
Leading Type: Non-small cell lung cancer, with 68.7% share in 2026
Leading Test: EGFR mutation test, with 40.8% share in 2026
Fastest-Growing Country: China, with 10.1% CAGR from 2026 to 2036
What Is Driving the Lung Cancer Diagnostics Market?

The expansion of targeted therapies and immunotherapies for non-small cell lung cancer is increasing demand for biomarker testing before treatment begins. Each additional targeted treatment indication can require a corresponding diagnostic assay, raising the number of molecular tests performed per patient and increasing diagnostic expenditure.

Comprehensive genomic profiling is becoming particularly relevant because laboratories can evaluate multiple actionable alterations through a consolidated testing workflow instead of relying on sequential single-gene tests. This shift can shorten the time required to establish a molecular profile and support treatment selection.

Lung cancer screening is another important demand catalyst. Low-dose CT programs are generating larger pools of patients with suspected pulmonary nodules, creating downstream demand for diagnostic confirmation, tissue analysis, and molecular characterization.

Liquid biopsy is also broadening the addressable testing opportunity. Blood-based assays can support EGFR resistance mutation detection, treatment monitoring, and emerging minimal residual disease applications, creating opportunities for repeat testing throughout the patient journey rather than limiting diagnostic activity to the initial tissue biopsy.

Why Is Non-Small Cell Lung Cancer the Leading Market Type?

Non-small cell lung cancer is expected to account for 68.7% of the market by type in 2026. Its leading position reflects the large diagnostic and therapeutic ecosystem surrounding NSCLC, particularly the expanding use of biomarker-directed treatment.

EGFR, ALK, PD-L1, and broader genomic markers have become increasingly relevant to treatment selection. As therapeutic options become more dependent on molecular characteristics, diagnostic providers are under pressure to deliver broader biomarker coverage while maintaining turnaround times compatible with oncology treatment decisions.

The growing adoption of comprehensive genomic profiling is therefore changing laboratory procurement priorities. Platforms that can accommodate expanding biomarker menus are positioned to benefit as oncologists increasingly require molecular information before selecting targeted or immune-based therapies.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-26251

How Is EGFR Testing Shaping Diagnostic Demand?

The EGFR mutation test is projected to hold 40.8% share in 2026, making it the leading test category in the lung cancer diagnostics market.

EGFR testing remains central to molecular characterization of eligible NSCLC patients because identifying actionable mutations can directly influence treatment selection. Demand is also being supported by the need to identify resistance-associated mutations during disease progression.

Liquid biopsy is adding another dimension to EGFR testing. When tissue is limited or repeat sampling is difficult, blood-based testing can provide an alternative source of molecular information. This supports a shift from a one-time diagnostic event toward repeat molecular assessment during treatment.

How Are AI and Molecular Technologies Changing Lung Cancer Detection?

AI-assisted CT interpretation is emerging as an important technology trend in lung cancer screening. Automated image analysis can help identify suspicious pulmonary nodules and support radiologists as screening volumes increase.

The impact extends beyond imaging. More effective nodule identification can increase the number of patients referred for confirmatory diagnostic procedures, creating downstream demand for pathology, molecular testing, and genomic profiling.

At the molecular level, comprehensive genomic profiling is consolidating testing workflows. Instead of ordering multiple assays independently, laboratories can increasingly use broader panels to identify actionable alterations in a single diagnostic process.

Liquid biopsy represents another technology transition. Its expanding role in resistance mutation detection and treatment monitoring is creating recurring testing opportunities that complement conventional tissue-based diagnosis.

What Are the Major Challenges Facing the Lung Cancer Diagnostics Market?

Reimbursement remains one of the principal constraints. Coverage for comprehensive genomic profiling and liquid biopsy differs across healthcare systems, creating uncertainty around testing utilization and laboratory investment.

The economic burden of advanced molecular diagnostics can also influence adoption in markets where healthcare budgets are constrained. Diagnostic providers must demonstrate that broader testing provides sufficient clinical value to justify reimbursement and procurement expenditure.

Another challenge is maintaining diagnostic accuracy while expanding test menus. As more biomarkers become clinically relevant, laboratories must manage increasingly complex workflows, quality requirements, and data interpretation needs.

Which Regions Are Showing the Strongest Growth?

· China is projected to record the fastest growth among the tracked countries, with a 10.10% CAGR between 2026 and 2036. Increasing diagnostic capacity, investment in healthcare infrastructure, and growing utilization of molecular testing are supporting market expansion.

· India follows with a 9.40% CAGR, reflecting increasing demand for advanced cancer diagnostics and broader access to molecular testing.

· Germany is forecast to expand at an 8.60% CAGR, while France records a 7.90% CAGR. The UK is expected to grow at 7.10%, supported by continued development of structured cancer diagnostic pathways.

· The USA is projected to expand at a 6.40% CAGR, representing a comparatively mature market with established screening, imaging, pathology, and molecular testing infrastructure.

· Brazil records a 5.60% CAGR, indicating continued expansion of lung cancer diagnostic capabilities as access to advanced testing develops.

Analyst Viewpoint

Anurag Sharma, Principal Analyst at Future Market Insights, states:

“Lung cancer diagnostics is moving from a diagnosis-first model toward a biomarker-led pathway in which imaging, pathology, and molecular testing increasingly work together. Comprehensive genomic profiling and liquid biopsy are especially important because they expand the role of diagnostics beyond initial confirmation and into treatment selection and monitoring.”

He adds, “The opportunity is substantial, but reimbursement will determine how quickly advanced testing moves from specialist centers into broader routine practice.”

Read the Full Market Report:
https://www.futuremarketinsights.com/reports/lung-cancer-diagnostics-market



What Is the Future Outlook for the Lung Cancer Diagnostics Market?

The lung cancer diagnostics market is expected to become increasingly integrated across imaging, pathology, molecular diagnostics, and longitudinal monitoring.

The market's USD 15.17 billion incremental opportunity through 2036 reflects more than rising diagnostic volumes. It also captures a shift in the composition of diagnostic spending toward higher-value molecular testing, comprehensive genomic profiling, liquid biopsy, and technology-assisted screening.

As targeted therapies continue to depend on accurate molecular characterization, diagnostic testing is becoming an increasingly important component of oncology treatment pathways. At the same time, AI-supported screening and liquid biopsy are broadening the diagnostic ecosystem beyond conventional tissue pathology.

Markets with expanding screening infrastructure and improving access to molecular testing are expected to provide significant opportunities, particularly China and India, which record projected CAGRs of 10.10% and 9.40%, respectively.

Frequently Asked Questions

1. What is the size of the Lung Cancer Diagnostics Market in 2026?

The Lung Cancer Diagnostics Market is projected to reach USD 14.30 billion in 2026.

2. What will the Lung Cancer Diagnostics Market be worth by 2036?

The market is forecast to reach USD 29.47 billion by 2036.

3. What is the CAGR of the Lung Cancer Diagnostics Market?

The Lung Cancer Diagnostics Market is expected to expand at a 7.50% CAGR from 2026 to 2036.

4. Which cancer type leads the Lung Cancer Diagnostics Market?

Non-small cell lung cancer leads by type, accounting for 68.7% share in 2026.

5. Which test segment dominates the Lung Cancer Diagnostics Market?

The EGFR mutation test leads by test, with an estimated 40.8% share in 2026.

6. Which country has the fastest growth outlook?

China is projected to register the fastest growth among the tracked countries, with a 10.10% CAGR from 2026 to 2036.

7. What technologies are creating new opportunities in lung cancer diagnostics?

Comprehensive genomic profiling, liquid biopsy, AI-assisted CT interpretation, EGFR resistance testing, and emerging minimal residual disease applications are creating new opportunities across the diagnostic pathway.

Report Scope

The Future Market Insights report on the Lung Cancer Diagnostics Market provides analysis of market size, growth trends, segment performance, country-level outlook, demand drivers, restraints, technological developments, and competitive dynamics. The study covers the historical period and forecast period through 2036 and includes 250 pages of detailed analysis.

Related Reports:

· Hand-held Breast Cancer Detection Market - https://www.futuremarketinsights.com/reports/hand-held-breast-cancer-detection-market

· Telehealth Therapy Services Market - https://www.futuremarketinsights.com/reports/telehealth-therapy-services-market

· Scapula Reconstruction Market - https://www.futuremarketinsights.com/reports/scapula-reconstruction-market

· Total Knee Replacement Market - https://www.futuremarketinsights.com/reports/total-knee-replacement-market

· NGS-based AMR Detection Market - https://www.futuremarketinsights.com/reports/ngs-based-amr-detection-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – [email protected]
For Media – [email protected]
For Web – https://www.futuremarketinsights.com